<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36952">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625480</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-104</org_study_id>
    <nct_id>NCT02625480</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia</brief_title>
  <acronym>ZUMA-4</acronym>
  <official_title>A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kite Pharma, Inc.</source>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and
      efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell
      therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in pediatric
      or adolescent subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Safety (Incidence of adverse events defined as dose-limiting toxicities (DLT)</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall complete remission rate</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Remission</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Residual Disease Negative Remission Rate</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allogeneic Stem Cell Transplant Rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KTE-C19</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed or refractory B-precursor ALL defined as one of the following:

               -  Primary refractory disease

               -  Relapsed or refractory disease after first or later salvage therapy

               -  Relapsed or refractory disease after allogeneic transplant provided subject is
                  at least 100 days from stem cell transplant at the time of enrollment

          2. Morphological disease in the bone marrow (≥ 5% blasts)

          3. Subjects with Ph+ disease are eligible if they are intolerant to tyrosine kinase
             inhibitor (TKI) therapy, or if they have relapsed/refractory disease despite
             treatment with at least 2 different TKIs

          4. Ages 2 to 21 at the time of Assent or Consent per IRB guidelines

          5. Lansky (age &lt; 16 years at the time of assent/consent) or Karnofsky (age ≥ 16 years at
             the time of assent/consent) performance status ≥ 80 at screening

          6. Adequate renal, hepatic, pulmonary and cardiac function defined as:

               -  Creatinine clearance ≥ 60 cc/min

               -  Serum ALT/AST ≤ 2.5 x ULN

               -  Total bilirubin ≤ 1.5 x ULN

               -  Cardiac ejection fraction ≥ 50% and no clinically significant ECG findings

               -  Baseline oxygen saturation &gt; 92% on room air

        Exclusion Criteria

          1. Diagnosis of Burkitt's leukemia/lymphoma according to WHO classification or chronic
             myelogenous leukemia lymphoid blast crisis

          2. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g.
             cervix, bladder, breast) unless disease free for at least 3 years

          3. Presence of CNS-3 disease and CNS-2 disease with neurological changes

          4. History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome,
             Shwachman-Diamond syndrome or any other known bone marrow failure syndrome

          5. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina,
             or other clinically significant cardiac disease within 12 months of enrollment

          6. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of
             enrollment.

          7. Primary immunodeficiency

          8. Known infection with HIV, hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV
             positive)

          9. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
             requiring IV antimicrobials for management.

         10. Prior medication:

               -  Prior CD19 directed therapy, including CAR+ T cell, BiTE, and antibody drug
                  conjugate (ADC), with the exception of subjects who received KTE-C19 in this
                  study and are eligible for re-treatment

               -  Treatment with alemtuzumab within 6 months prior to leukapheresis, or treatment
                  with clofarabine or cladribine within 3 months prior to leukapheresis

               -  Donor lymphocyte infusion (DLI) within 28 days prior to enrollment

               -  Any drug used for GVHD within 4 weeks prior to enrollment

         11. Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by IBMTR index; acute
             or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment

         12. Live vaccine ≤ 6 weeks prior to start of conditioning regimen

         13. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the preparative chemotherapy on the fetus or infant.
             Females who have undergone surgical sterilization are not considered to be of
             childbearing potential

         14. Subjects of both genders of child-bearing potential who are not willing to practice
             birth control from the time of consent through 6 months after the completion of
             KTE-C19
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajul Jain, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Kite Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison Bowen, MPM, PMP, BS, BA</last_name>
    <phone>(404) 792-7824</phone>
    <email>allison.bowen@theoremclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Rosenthal, MD</last_name>
      <email>jrosenthal@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Sarmad Bahrani</last_name>
      <email>sbahrani@coh.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Wayne, MD</last_name>
      <email>awayne@chla.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Reed</last_name>
      <email>kreed@chla.usc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Sender, MD</last_name>
      <email>lsender@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Gates, RN</last_name>
      <email>lgates@choc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Childrens Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Schwartz</last_name>
      <email>Stephanie.Schwartz@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia Gore, MD</last_name>
      <email>lia.gore@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pat Rice</last_name>
      <email>willipa@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Genevieve Courpas</last_name>
      <email>gcourpa1@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Brown</last_name>
      <email>Anastasia.Brown@ChildrensMN.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Schott</last_name>
      <email>schott.debra@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Perez</last_name>
      <email>gina.perez@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Stults</last_name>
      <email>amanda.a.stults@vanderbilt.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helton Cruz</last_name>
      <email>hdcruz@texaschildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Pritchard</last_name>
      <email>jep@virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Fielbelkorn</last_name>
      <email>afiebelk@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Rehborg</last_name>
      <email>rrehborg@mcw.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>December 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
